



# Where Acne Meets *Innovation*



DISTRIBUTÖR

SVERIGE - NORGE - DANMARK



[www.derma.gonorthmedical.com](http://www.derma.gonorthmedical.com)

# The Future of Acne Treatment

AviClear is the first and original FDA-cleared laser for the long-term treatment of mild, moderate, and severe inflammatory acne.\*

AviClear uses a 1726 nm wavelength to selectively deliver energy, damaging the sebocytes and suppress sebum production without compromising the epidermis.



Long-lasting, durable results<sup>1</sup>



Safe for all skin types and tones in both adolescents and adults



Three quick, 30-minute treatment sessions<sup>2</sup>



Model. Not actual patient.

\*AviClear is Health Canada and TGA approved for the treatment of acne scars.

## The Demand Is Clear

Not only does AviClear **meet the demand for the #1 dermatologic condition in the US**, but it's also a lasting, **durable solution** for mild, moderate, and severe inflammatory acne.<sup>3,4</sup>

**\$5B**

estimated U.S. acne treatment market size in 2022.<sup>5</sup>


**48%**

of patients are unsatisfied with their current acne treatment.<sup>6</sup>


# Treat Acne at the Source

Research indicates that at 1726 nm, pure sebum absorbs approximately 2x more energy compared to H<sub>2</sub>O.<sup>7</sup>

AviClear selectively delivers energy to damage the sebocytes and suppress sebum production without compromising the epidermis.<sup>4</sup>



The proven **1726 nm** wavelength selectively delivers energy to the sebaceous gland.



The heat damages the sebocytes and suppresses sebum production, while other chromophores and the epidermis remain intact.

## AviCool™

AviClear is designed with the exclusive AviCool technology. The combination of sapphire contact cooling and smart sensors provides a safe and comfortable treatment experience.<sup>1\*</sup>

Patients have described the sensation of AviClear treatments like a "slight snapping against the skin."<sup>1\*</sup>




The median score for treatment comfort was 5 on a scale of 1-10.<sup>1</sup>

\* Patient comfort and experience may vary.



# The Results Are Clear<sup>1</sup>

The pivotal study for AviClear was an open-label study of 104 patients of any skin type and with mild, moderate, or severe inflammatory acne vulgaris.



Important safety and risk information about AviClear is available by contacting Cutera at [www.cutera.com/us-en/global-offices](http://www.cutera.com/us-en/global-offices). Patients should talk to their healthcare provider.



# Results that Redefine What's Possible

**AGE: 18 | SKIN TYPE: V**  
**SEVERITY:** Improved from Moderate to Clear



**AGE: 23 | SKIN TYPE: IV**  
**SEVERITY:** Improved from Moderate to Almost Clear



**AGE: 18 | SKIN TYPE: IV**  
**SEVERITY:** Improved from Severe to Clear



**AGE: 25 | SKIN TYPE: III**  
**SEVERITY:** Improved from Moderate to Almost Clear



Individual results may vary.

Important safety and risk information about AviClear is available by contacting Cutera at [www.cutera.com/us-en/global-offices](http://www.cutera.com/us-en/global-offices). Patients should talk to their healthcare provider.

# Technical Specifications

Wavelength	1726 nm (nominal)
Maximum Output Power	100 W
Maximum Fluence	Up to 30 J/cm <sup>2</sup>
Spot size (Area)	3.0 mm (0.07 cm <sup>2</sup> )
Treatment scan patterns	Single Spot; 7-spot Hexagonal Array
Cooling Window Temperature	0° C to 5° C
Console dimensions (D x W x H)	24.5 x 19 x 38 in. (0.62 x 0.48 x 0.97 m)
Console weight	125 lbs. (56.7 kg)

CUTERA®



Become a provider today.  
Scan for more information.

[www.aviclear.com](http://www.aviclear.com)

Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients.

For more information, call 1-415-657-5500 or 1-888-4CUTERA or visit [www.cutera.com](http://www.cutera.com).

## Important Safety Information:

The following treatment-related expected transient side effects and possible adverse events may occur during or following treatment with AviClear: Discomfort; Erythema; Edema; Transient acne flareups; Temporary skin dryness; Blisters; Crusting/Scabbing; Hyperpigmentation; Skin texture changes; Infection; Scarring; Hypopigmentation; Altered hair growth. Do not use AviClear if you are pregnant or have skin cancer. Additional contraindications can be discussed during a treatment consultation.

**References:** 1. Data on file. FDA clearance study. Cutera, Inc. 2. Data on file. Cutera, Inc. 3. American Academy of Dermatology. Skin conditions by the numbers. Available at <https://www.aad.org/media/stats-numbers#:~:text=Acne%20is%20the%20most%20common,to%2050%20million%20Americans%20annually.&text=Acne%20usually%20begins%20in%20puberty%20and%20affects%20many%20adolescents%20and%20young%20adults>. Last accessed February 27, 2024. 4. Goldberg D, et al. Selective photothermolysis with a novel 1726 nm laser beam: A safe and effective solution for acne vulgaris. *J Cosmet Dermatol*. 20023 Feb;22(2):486-496. 5. Fortune Business Insights. U.S. acne treatment market size, share and covid-19 impact analysis, by product type (retinoids, antibiotics, isotretinoin, and others), by treatment modality (oral and topical), by age group (10 to 17, 18 to 44, 45 to 64, and 65 and above), by distribution channel (hospital pharmacies and retail pharmacies), and country forecast, 2023-2030. 2023;Report ID: FBI106565. young%20adults. Last accessed February 27, 2024. 6. Hayran Y, et al. Factors affecting adherence and patient satisfaction with treatment: a cross-sectional study of 500 patients with acne vulgaris. *J Dermatolog Treat*. 2021 Feb;32(1):64-69. 7. Sakamoto FH, et al. Selective photothermolysis to target sebaceous glands: theoretical estimation of parameters and preliminary results using a free electron laser. *Lasers Surg Med*. 2012;44(2):175-183.